EUVIMEDEUVIMED entdecken
Crossref

Predicting oral cephalosporin susceptibility in Escherichia coli blood isolates using parenteral cephalosporin susceptibility testing

Tho H Pham iD, Kyle C Molina, Vanthida Huang iD

Journal of Antimicrobial Chemotherapy · 04.03.2026 · 81 (4)

DOI: 10.1093/jac/dkag093 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 17.03.2026. Verfasst von Tho H Pham und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, University of Arizona R. Ken Coit College of Pharmacy, Phoenix, AZ, USA. Hauptthemen laut MEDLINE: Escherichia coli, Anti-Bacterial Agents, Cephalosporins, Escherichia coli Infections. Die Arbeit nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Oral second- and third-generation cephalosporins are increasingly used as transitional therapy for Escherichia coli bloodstream infection, particularly in patients with resistance and intolerance to first-line agents. However, many automated antimicrobial susceptibility testing (AST) systems only assess parenteral cephalosporins, potentially delaying transitions of care. Limited data exist on the correlation and surrogacy between parenteral and oral cephalosporin AST. We aimed to determine whether AST for parenteral cefazolin, ceftriaxone or cefotaxime can serve as surrogates to predict susceptibility for oral cephalosporins.

Methods

E. coli blood isolates susceptible to parenteral third-generation cephalosporins were consecutively collected from unique patients from two health systems in Phoenix, AZ, USA from January 2021 to 2023. Broth microdilution was performed according to CLSI. Categorical agreement (CA) rates were calculated using cefazolin, ceftriaxone, or cefotaxime as the surrogate antibiotic for oral cephalosporins (cefuroxime, cefaclor, cefprozil, cefdinir, cefpodoxime, cefixime). Discrepancies were classified as minor errors (mE), major errors (ME), or very major errors (VME) per CLSI.

Results

Among 200 isolates, susceptibility to cefazolin at MIC ≤2 mg/L, cefazolin at MIC ≤16 mg/L, ceftriaxone and cefotaxime at MIC ≤1 mg/L were 43%, 91.5% and 100%, respectively. Cefazolin MIC ≤2 mg/L provided high CA across oral cephalosporins but excessive mE (25%–37%) and ME (20%–40%) rates. Ceftriaxone and cefotaxime achieved 100% CA for oral third-generation cephalosporins with mE rates within acceptable limits; however, CA was suboptimal for oral second-generation agents (83%–88%). No surrogate antibiotic met acceptable CLSI criteria due to lack of CA, however, ceftriaxone/cefotaxime achieved acceptable limits in CA, mE, ME and VME.

Conclusions

Prediction of oral second-generation cephalosporins may warrant cefazolin MIC ≤2 mg/L, despite limitations regarding false resistance and susceptibility discordant. Ceftriaxone/cefotaxime demonstrates a more reliable surrogate for predicting oral third-generation cephalosporins susceptibility. Future investigations are necessary to clinically corroborate these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Escherichia coliAnti-Bacterial AgentsCephalosporinsEscherichia coli InfectionsHumansMicrobial Sensitivity TestsThird Generation CephalosporinsAdministration, OralSecond Generation CephalosporinsCefazolinCeftriaxoneBacteremiaCefotaxime

Substanzen

Anti-Bacterial AgentsCephalosporinsThird Generation CephalosporinsSecond Generation CephalosporinsCefazolinCeftriaxoneCefotaxime

Autor:innen und Institutionen

  • Department of Pharmacy Practice, University of Arizona R. Ken Coit College of Pharmacy, Phoenix, AZ, USA.
  • Department of Pharmacy, Scripps Health, San Diego, CA, USA.
  • Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, USA.
  • Department of Pharmacy Practice, Midwestern University College of Pharmacy-Glendale Campus, Glendale, AZ, USA.

ORCID-Profile: Tho H Pham, Vanthida Huang

Zitieren

APA

Pham, T. H., Molina, K. C., & Huang, V. (2026). Predicting oral cephalosporin susceptibility in Escherichia coli blood isolates using parenteral cephalosporin susceptibility testing. Journal of Antimicrobial Chemotherapy, 81(4). https://doi.org/10.1093/jac/dkag093

Vancouver

Pham TH, Molina KC, Huang V. Predicting oral cephalosporin susceptibility in Escherichia coli blood isolates using parenteral cephalosporin susceptibility testing. Journal of Antimicrobial Chemotherapy. 2026;81(4). doi:10.1093/jac/dkag093

BibTeX
@article{Pham2026,
  author = {Pham, Tho H and Molina, Kyle C and Huang, Vanthida},
  title = {Predicting oral cephalosporin susceptibility in Escherichia coli blood isolates using parenteral cephalosporin susceptibility testing},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  volume = {81},
  number = {4},
  doi = {10.1093/jac/dkag093}
}
Kostenlos starten →